Transcript The Gerolymatos Group

Medexis SΑ
Translating Basic Science into Value
5th Venture Capital Forum
Athens, 16-17 June 2004
Member of
Group
Medexis Presentation: Overview
Corporate Profile & Mission
The Gerolymatos Group
Structure & Organization
Corporate Strategy
Research & Development
Project Portfolio
Conclusions
Member of
Group
Corporate Profile & Mission
 Incorporated in 2002, fully owned by the Gerolymatos Group
of Companies.
 Biotechnology Venture of the Group focusing on Research &
Development activities in Greece.
 Medexis’s strategic objective is to identify, develop and
commercialize novel therapeutic molecules and technologies
for the treatment of critical diseases in human patients.
Member of
Group
The Gerolymatos Group
 Active in the Health & Beauty Business for more than 80 years.
 Product range includes: Pharmaceuticals, OTC, Diagnostics,
Veterinary, Cosmetics, and Consumer products.
 Custom manufacturing & distribution for third parties.
 Warehousing space 13,000 m2.
 Three production plants for pharmaceuticals & cosmetics.
Member of
Group
The Gerolymatos Group
 Offices in Athens, Kryoneri and Salonica.
 Exports to more than 20 countries.
 Subsidiaries: 6 in Greece + 6 Abroad.
 >850 Employees.
 2003 Sales: € 165.4 million.
Member of
Group
Structure & Organization
 Located in Kryoneri, Corporate Headquarters
 Utilizes Corporate resources
 Management & Marketing experience of the Group
Member of
Group
Structure & Organization
 Extensive network of scientific advisors
 Intellectual property experts
 100% of the budget devoted to R & D activities
The only company investing in Greek biotech research
Scientific Advisory Board
•
•
•
•
•
Prof. Christos Stournaras (Medical School, University of Crete)
Dr. Nikos Bakopoulos (Chief Executive Officer, Aton Pharma Inc)
Dr. George Pavlakis (Head of Retroviral Section, National Cancer Institute)
Dr Aris Persidis (VP Research & Development, Upstate Inc)
Dr Basil Theofanopoulos (General Manager, Gerolymatos Inc)
Member of
Group
Corporate Strategy
 Medexis seeks, evaluates and selectively invests in early
stage R & D projects with commercial potential that are
being developed in Greek Academic Institutions with an
aim to develop novel therapeutic treatments.
 Areas of therapeutic interest include:
•
•
•
•
Cancer
CNS Diseases
Infectious Diseases
Inflammation & Wound healing
Member of
Group
Corporate Strategy
Strategic contacts and alliances with prominent Greek Research
Institutes allow for identification of interesting IP
Assignment of the commercial exploitation of the invention in
exchange to royalties on future profits (in-licensing)
R & D funding according to specific scientific milestones
Development of IP portfolio
Development of product candidates from an early pre-clinical to
a late-preclinical stage (IND) or phase I before partnering with a
strategic ally (out-licensing)
Member of
Group
Research & Development
In -Licensing
Out -Licensing
Discovery
Phase I
0
Full Development
Drug Evaluation
5
Idea
Phase III
Phase II
10
Drug
12 -15 Years
Develop therapeutic molecules from an early pre-clinical to a late
pre-clinical stage (IND) or phase I.
Out – license project to a strategic partner(s) in exchange of cash
down payments, milestone payments and royalties.
Member of
15
Group
Research & Development
In -Licensing
Out -Licensing
Discovery
Phase I
0
Phase III
Phase II
5
Idea




Full Development
Drug Evaluation
10
Drug
12 -15 Years
Scientific Innovation & Excellence
IP Evaluation and Patentability
Commercial Potential/Business Risk
Regulatory
Member of
15
Group
Project Portfolio
Gerolab Project
•Pharmaceutical formulations comprising labdanes for the treatment of
tumors and leukemia.
CastBSA Project
•Steroid-protein conjugates for the treatment of tumors and hematological
malignancies.
Angiomed Project
•Novel angiogenic molecules for the treatment of cancer and ophthalmic
disorders.
Member of
Group
Project Portfolio
Gerolab Project
•R & D Status:
•Patent Status:
Proof-of-concept, colon cancer
GR 1003509, US 6,652,877, AU 773462
PCT/GR00/00033 (WO 01/34116) pending in EPO, Canada, Japan
CastBSA Project
•R & D Status:
•Patent Status:
Proof-of-concept, prostate cancer
GR 1004274
PCT/IB03/02785 (WO 04/06966) pending for 122 countries
Angiomed Project
•R & D Status:
•Patent Status:
Proof-of-concept, neuroblastomas
GR 20030100319, GR20030100362, pending
US 60/493.975, US 60/502.047, pending
Member of
Group
Project Portfolio
Helixplast
Medical Device of class IIb based on Helixderm®, a pharmaceutical
product of herbal origin approved by EOF for wound healing.
CE Mark
Launch in Greece & Europe within 2005
Member of
Group
Conclusions
Medexis focuses on early stage biotechnology projects aiming at the
development of novel therapeutic applications.
Medexis promotes technology transfer from the Academic Institutions
to the industry financing Research & Development and developing the
product IP portfolio.
Medexis’s strategic goal is to develop product candidates to a late preclinical stage (IND) or phase I and collaborate with a strategic partner for
further development/clinical testing of the products.
Medexis’s portfolio consists of three anti-cancer projects currently at
the proof-of-concept stage in animal models of cancer.
Member of
Group
Medexis SΑ
Translating Basic Science into Value
5th Venture Capital Forum
Athens, 16-17 June 2004
Kostantinos Alevizopoulos Ph.D.
Medexis SA
[email protected]
Member of
Group